Urology and Women’s Health Panelists Selected in OneMedForum SF 2011

Urology and women’s health have been areas of substantial M&A activity during the last 10 years as the major medtech consolidators have been busy building separate business units to address these medical needs. This panel includes representatives from several large medtech acquirers, as well as venture and private equity firms with major investments in this field. The panelists will explore exciting new products under development and the issues facing this dynamic market.

“Urology and Women’s Health are important areas with major unmet medical needs,” said  Casey McGlynn, a partner at Wilson Sonsini Goodrich & Rosati, and panel moderator. “Many startups in this area are addressing large markets with less invasive approaches which offer the payor reduced costs and the patient less morbidity and faster recoveries.  This is going to be an area with several major acquisitions in the near future.”

Casey serves as a member of the board of directors at Wilson Sonsini Goodrich & Rosati and since joining the firm in 1978, he has been a member of the firm’s Policy, Nominating, and Compensation Committees.  Mr. McGlynn is a nationally recognized leader in the representation of start-up and growth technology companies. He was recognized in the 2006, 2007, 2008, 2009, and 2010 editions of Chambers USA: America’s Leading Lawyers for Business, most recently in the top tier of California life sciences attorneys.

Panelists include: Benjamin J. Daverman, Vice President of GTCR Golder Rauner. Prior to joining GTCR, he worked as a venture capitalist at Alta Partners. He holds an MBA from the Wharton School at the University of Pennsylvania and a BA in History from Colgate University.

Jan Garfinkle, Managing Partner at Arboretum Ventures spent 20 years in senior management positions within entrepreneurial healthcare companies prior to founding Arboretum in 2002. She worked for two successful medical device start-up companies, both of which she joined early in its development and held key management roles in marketing, clinical research, and sales and successfully launched over 20 new medical products.

David Amerson, Global Vice President of Coloplast Surgical Urology is currently responsible for over $150 million of revenue in the urology market. His over twenty-one years of management experience in the medical field include sales and marketing careers at Osbon Medical Systems (a medical device start-up that manufactured a pioneering non-invasive therapy for erectile dysfunction) and Mentor Corporation (an established company in the aesthetic medicine and surgical urology fields, for which he served as vice president).

The comments are closed.